HomeADVM • NASDAQ
add
Adverum Biotechnologies Inc
Previous close
$9.39
Day range
$9.11 - $10.10
Year range
$7.10 - $29.70
Market cap
190.74M USD
Avg Volume
282.98K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 0.00 | — |
Operating expense | 10.66M | 23.66% |
Net income | -23.71M | 27.56% |
Net profit margin | — | — |
Earnings per share | -2.30 | 30.30% |
EBITDA | -24.92M | 9.08% |
Effective tax rate | 4.56% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 96.53M | -47.99% |
Total assets | 173.01M | -43.90% |
Total liabilities | 89.54M | -29.41% |
Total equity | 83.47M | — |
Shares outstanding | 20.75M | — |
Price to book | 1.14 | — |
Return on assets | -35.07% | — |
Return on capital | -38.51% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -23.71M | 27.56% |
Cash from operations | -21.33M | -15.44% |
Cash from investing | -9.88M | -542.17% |
Cash from financing | 166.00K | -31.40% |
Net change in cash | -31.04M | -94.01% |
Free cash flow | -14.00M | -189.85% |
About
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration. Wikipedia
Founded
Jan 1, 2006
Headquarters
Website
Employees
121